🌟 Meet us at the 39th Annual International Clinical Cytometry Meeting 🌟 Connect with Chelsea Riveley and Jackie Naik at ICCS 2024 to discuss how our advanced clinical specialty testing platforms can elevate and accelerate your clinical trials. Don't miss this opportunity to explore our clinical testing platforms. 📅 Schedule a meeting with our team today: https://hubs.li/Q02Nr3PT0 #ICCS2024 #ClinicalTesting #biomarkers #clinicaltrials #clinicalspecialtytesting #flowcytometry #Immunoassays
Champions Oncology, Inc.
Biotechnology
Hackensack, New Jersey 9,194 followers
US-based, End-to-End Oncology Pharmacology Solutions CRO
About us
Champions Oncology, Inc. provides an end-to-end range of research and development solutions and services that improve the productivity of oncology drug development. Using both in vitro to in vivo testing platforms companies can leverage the expertise at Champions Oncology to help guide decision making for clinical development scenarios. From screens using commercially-available and custom cell lines, to studies leveraging syngeneic or traditional patient-derived studies xenograft (PDX) models, and modeling treatment response in the clinic, Champions Oncology is your partner in meeting today’s needs and innovating for tomorrow’s challenges. At the core of our services is the Champions TumorGraft® (CTG) platform, a comprehensive, unique compendium of PDX models that preserve the biological characteristics of human tumors and are highly predictive of clinical outcomes. Services utilizing Champions TumorGrafts® PDX tumor models include evaluating tumor sensitivity/resistance to various single, combination, standard and novel chemotherapy agents, biomarker discovery and the identification of novel drug combinations. Champions TumorGraft® PDX models are procured through agreements our Clinical Collaboration Network, a series of renowned oncology institutions in the US and around the world, as well as through the company’s Personalized Oncology Solutions business. Personalized Oncology Solutions assist clinical oncologists by establishing and administering expert tumor panels for their patients to analyze medical records and test results, to assist in understanding conventional and experimental options and to identify and arrange for testing, analysis and study of the patients’ cancer tissues, as appropriate. Additionally, the company offers personalized PDX development, drug studies and genome sequencing, whereby physicians evaluate the effects of cancer drugs and understand the genetic makeup of each patient’s tumor, enabling them to better select treatment regimens.
- Website
-
http://www.championsoncology.com
External link for Champions Oncology, Inc.
- Industry
- Biotechnology
- Company size
- 51-200 employees
- Headquarters
- Hackensack, New Jersey
- Type
- Public Company
- Founded
- 2007
- Specialties
- Translational Oncology Research, Personalized Oncology, Patient Derived Xenograft, Oncology Pharmacology, Immuno-Oncology, Flow Cytometry, Syngeneic Models, Humanized Mouse Models, GCP, Clinical Flow Cytometry, PDX, 3D Organoid Models, and Clinical Specialty Testing
Locations
-
Primary
Hackensack
Hackensack, New Jersey 07601, US
-
1330 Piccard Dr
Suite 025 & 104
Rockville, Maryland 20850, US
-
Via L. Ariosto 21, 1st Floor
Bresso MI, 20091, IT
-
4 Oppenheimer St., Ha’ogen Building B
Rehovot, 7670104, IL
Employees at Champions Oncology, Inc.
Updates
-
We're #hiring a new Study/Project Coordinator, Formulation Services in Rockville, Maryland. Apply today or share this post with your network.
-
📢 Don’t miss our upcoming webinar on September 5th with our immuno-oncology expert Dr. Mara Gilardi, titled "How to Design a Successful 3D Tumor Model Co-Culture Study." Join us to explore key strategies for designing effective ex vivo 3D tumor model co-culture studies and take your oncology drug development to the next level. Register now! 🌟 #ImmunoOncology #tumorgraft3d #organoid #3dtumormodel #exvivo #CancerTreatment #OncologyInnovation #ImmunoTherapeutics #CancerTreatment ##CancerImmunotherapy #organoids #Coculture
🚨New Webinar Alert: Join Champions for our upcoming webinar 🚨 How to Design a Successful 3D Tumor Model Co-Culture Study Thursday September 5th, 2024 4pm CEST ◾10am EST ◾7am PST Save your spot: https://lnkd.in/ggtTCAq9 Join us for an insightful webinar with our immuno-oncology expert Dr. Mara Gilardi. This session will guide you through different aspects of designing an effective ex vivo 3D tumor model co-culture studies, focusing on model selection, donor choice, optimizing tumor-to-immune cell ratios, selecting controls, and choosing key readouts. Learn how to elevate your research with advanced 3D tumor models for more impactful oncology studies. #ImmunoOncology #tumorgraft3d #organoid #3dtumormodel #exvivo #CancerTreatment #OncologyInnovation #ImmunoTherapeutics #CancerTreatment ##CancerImmunotherapy #organoids #Coculture
This content isn’t available here
Access this content and more in the LinkedIn app
-
📢 New Pretreated Models are Available Now! Champions is now offering 5 new PDX models pretreated with the latest cancer therapies to our bank for immediate use in ex vivo and in vivo studies. ✳️CTG-4149 - TNBC pretreated with Keytruda (autologous TILs and PBMCs available) ✳️CTG-3884 - TNBC BRCA1m pretreated with niraparib ✳️CTG-4243 - Melanoma BRAF V600F pretreated with dabrafenib ✳️CTG-4079 - NSCLC pretreated with Keytruda (autologous PBMCs available) ✳️CTG-4138 - RCC pretreated with Keytruda (autologous PBMCs available) #PDXmodels #cancertherapy #cancerresearch #cancer #oncologyresearch #oncology #pretreatedmodels #TNBC #NSCLC #melanoma #RCC #renalcellcarcinoma #keytruda #niraparib #dabrafenib #BRAF #BRAFV600F #BRCA #BRCA1 #TIL #PBMC #autologousTILs #autologousPBMCs
-
Designing the best Mouse Clinical trial (MCT) is vital to the success of your research. MCTs can help reveal data that can accelerate the development of effective cancer therapies, ultimately improving patient outcomes. Learn more about powering the study, selecting models, preparing the dataset, identifying biomarkers, and integrating proteomics which can lead to a successful MCT. Read the blog: https://hubs.li/Q02MZtgJ0 #CancerResearch #Cancer #Oncology #OncologyResearch #MouseClinicalTrial #MCT #Lumin #LuminAcuity #PDX #Blog
-
🌟 Join us at the 12th Annual Outsourcing in Clinical Trials 2024 Conference 🌟 Connect with our team at the OCT 2024 conference to discuss how our advanced specialty testing platforms can elevate and accelerate your clinical trials. Don't miss this opportunity to explore our innovative solutions. 📅 Schedule a meeting with us today: https://hubs.li/Q02MzXZy0 #OCT2024 #ClinicalTesting #biomarkers #clinicaltrials #clinicalspecialtytesting #flowcytometry #Immunoassays
-
-
🌟We’re thrilled to announce that Dr. Benedetta Arno, Lead Scientist Medicines Discovery Catapult, will be speaking at the Champions’ Translational Oncology Symposium in Boston, MA, on September 17th! Dr. Arno is a leading expert in radiopharmaceutical drug development, and her insights into translational research are set to be one of the highlights of the symposium. The symposium is complimentary to attend, but seats are limited. Don’t miss your chance to engage with top industry experts and gain cutting-edge knowledge in radiopharmaceuticals. 👉 Register today to secure your spot and attend Dr. Arno's talk in person: https://hubs.li/Q02LX_kJ0 #cancerresearch #radiopharmaceuticals #radioligands #Cancertherapy #oncology #Translationaloncology #cancerresearch #targetedtherapy #immunooncology
-
-
🚀Accelerate your lymphoma program with an exclusive DLBCL PDX model, CTG-3879, derived from a patient who progressed on combination therapy with lenalidomide and tafasitamab-cxix, an anti-CD19 antibody, post-collection. Autologous PBMCs are also available for this DLBCL PDX model, allowing you to precisely investigate your agent's impact on the immune system and its role in eliminating DLBCL cells. Check out Champions' DLBCL Model Cohort sheet to learn more about our patient-derived DLBCL Models: https://hubs.li/Q02LK0dY0 #DLBCL #lymphoma #oncologyresearch #oncology #cancerresearch #cancer #heme #CD19 #modelspotlight
-
-
📃Champions recently collaborated with Children's Cancer Therapy Development Institute on a study that was published in Nature Scientific Reports supporting the use of entinostat as a combinatorial therapeutic for rhabdomyosarcoma (RMS). Learn how to accelerate your sarcoma pipeline with our broadly characterized and clinically relevant PDX models. Read the publication: https://hubs.li/Q02Md2ds0 #Oncology #Sarcoma #OncologyResearch #CancerResearch #pediatriccancer #childhoodcancer #ccTDI
-
-
Assessing gene expression by GCLP-compliant qPCR can be critical for clinical trial biomarker monitoring and patient segmentation. Champions provides superior clinical qPCR specialty testing services through: ▪️ Flexible and custom services to support a variety of clinical applications ▪️ Rapid results to reveal critical insights ▪️ Expertise in multiple therapeutic areas and sample types Learn more about Champions' clinical specialty testing services: https://hubs.li/Q02LK20d0
-